Literature DB >> 1700066

The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope.

H Meyer1, Y Masuho, M Mach.   

Abstract

The glycoprotein complex gp58/116 of human cytomegalovirus (HCMV) represents a dominant antigen for the humoral immune response. We have used the human monoclonal antibody C23, which is capable of neutralizing HCMV in tissue culture without the addition of complement, to study the origin of gp116 as well as the amino acid sequence recognized by the antibody. Our results show that gp116 is derived from the same open reading frame as gp58 and that it represents the amino-terminal portion of the precursor protein. Using prokaryote-expressed beta-galactosidase-gp116 fusion proteins, the binding site of C23 was located to between amino acids 27 to 84 of the amino-terminal portion of gp116. Analyses of HCMV-positive human sera revealed that this portion of the molecule is immunogenic during natural infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1700066     DOI: 10.1099/0022-1317-71-10-2443

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  24 in total

1.  Furin is involved in baculovirus envelope fusion protein activation.

Authors:  Marcel Westenberg; Hualin Wang; Wilfred F J IJkel; Rob W Goldbach; Just M Vlak; Douwe Zuidema
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus.

Authors:  B Wagner; B Kropff; H Kalbacher; W Britt; V A Sundqvist; L Ostberg; M Mach
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

3.  Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus.

Authors:  Christy A Thomson; Steve Bryson; Gary R McLean; A Louise Creagh; Emil F Pai; John W Schrader
Journal:  EMBO J       Date:  2008-09-04       Impact factor: 11.598

4.  Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques.

Authors:  M Ohlin; M Silvestri; V A Sundqvist; C A Borrebaeck
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

5.  Comparative sequence analysis of human cytomegalovirus strains.

Authors:  R Lehner; T Stamminger; M Mach
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

6.  Cell Fusion Induced by a Fusion-Active Form of Human Cytomegalovirus Glycoprotein B (gB) Is Inhibited by Antibodies Directed at Antigenic Domain 5 in the Ectodomain of gB.

Authors:  Nina Reuter; Barbara Kropff; Julia Karin Schneiderbanger; Mira Alt; Adalbert Krawczyk; Christian Sinzger; Thomas H Winkler; William J Britt; Michael Mach; Marco Thomas
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

7.  Antigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B.

Authors:  William J Britt; Michael A Jarvis; Derek D Drummond; Michael Mach
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

8.  Sequence variation of the amino-terminal antigenic domains of glycoprotein B of human cytomegalovirus strains isolated from Chinese patients.

Authors:  S Y Shiu; K M Chan; S K Lo; K W Ip; K Y Yuen; R B Health
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific.

Authors:  M Urban; W Britt; M Mach
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

10.  Molecular fine-specificity analysis of antibody responses to human cytomegalovirus and design of novel synthetic-peptide-based serodiagnostic assays.

Authors:  A E Greijer; J M van de Crommert; S J Stevens; J M Middeldorp
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.